USANZ WA Section Annual Scientific Meeting - Urological Society of ...

USANZ WA Section
Annual Scientific Meeting
Caves House Hotel
Yallingup
14-16 September 2012

Welcome
Dear Delegates and Sponsors
The WA Section of USANZ would like to extend to you and your family a very warm welcome to the 2012
Annual Section Meeting. We would like to extend an especially warm welcome to our guests, A/Prof Nathan
Lawrentschuk, Prof Louis Landau, Dr David Millar , Dr Prashant Patel and Dr Jim Anderson.
We also extend a warm welcome to USANZ CEO, Michael Nugara; USANZ President, Dr Stephen Ruthven
and his wife Robyn are unable to attend and extend their apologies.
I hope you find the meeting both educational and enjoyable.
Best wishes
Melvyn Kuan
Convenor—2012 WA State Section Meeting

Sponsors
Thank you
The Western Australia Section of the Urological Society of Australia and New Zealand is grateful
for the support and sponsorship of the following companies:
Gold Sponsors
Silver Sponsors
Bronze Sponsors
Speaker Sponsor

Invited Speakers
A/Prof Nathan Lawrentschuk
Nathan Lawrentschuk is a specialist in urological cancer surgery. After medical
school at the University of Melbourne, Australia, he completed his internship and
basic surgical training at the Royal Melbourne Hospital. He trained in urology at
the Royal Australasian College of Surgeons and also completed a PhD in kidney
cancer through the University of Melbourne and the Ludwig Institute for Cancer
Research. He developed his expertise in urological cancers and trained in robotic
surgery at the University of Toronto, Princess Margaret Hospital in Toronto,
Canada.
Sponsored by
Prof Louis Landau
Professor Louis Landau is Chair of the Postgraduate Medical Council of Western
Australia, and former Dean of the Faculty of Medicine and Dentistry (UWA),
Emeritus Professor of Paediatrics (Princess Margaret Hospital)
Principal Medical Advisor, Medical Workforce at the Department of Health!
Prof Wilhelm Bauer
Dr. Wilhelm Bauer is a laparoscopic urologist from Vienna, Austria, trained in the
most modern laparoscopic techniques and specialising in laparoscopic radical
prostatectomy, radical cystectomy and nephrectomy as well as the surgical treatment
of male incontinence. Dr. Bauer is the leading expert worldwide on use of
the adjustable ATOMS System for male urinary incontinence after radical prostatectomy,
having implanted more than 200 systems since the product’s inception.
In addition to holding some 30 surgical workshops during the last four years in
Austria, Dr. Bauer has also performed live surgery on more than 35 occasions at
various conferences, meetings and workshops throughout Europe, as well as in
Hong Kong and Australia
Dr Prashant Patel
Prashant Patel qualified in 1992 from India and then trained to qualify as a General
surgeon with special interest in pelvic surgery. He was awarded a PhD from
the University of Birmingham whilst training to qualify as a Urologist. His research
explored gene and immunotherapy for prostate cancer. Upon completion of Urology
training in the UK, he travelled to Perth, Australia to complete a fellowship in
urological cancer surgery. Upon Mike Wallace's retirement, he commenced his
appointment in 2010 as a Senior Lecturer in Urology at the University of Birmingham
and Consultant Urological Surgeon at QE Hospital to pursue a joint career in
academic and clinical urology. His academic interests are to explore molecular
markers in bladder cancer on the back of BCPP and immunotherapeutic approaches
in all urological cancers. His clinical interests are in pelvic and testicular cancer
and conduct clinical trials in urological cancers.

Invited Speakers
Dr David Millar
Dr David Millar comes to Sexual Medicine after working for many years in Sports
Medicine and Occupational Health.
He has taken over what is now called WA Sexual Health Centre upon invitation
from Dr Denis Cherry. He has been well trained by Denis who remains on as Mentor
and Researcher for the Clinic. He is thoroughly enjoying this area of work and
the opportunity it gives to inspire patients to make positive lifestyle changes.
Outside of Medicine he is a family guy, loves sailing and kitesurfing, the latter of
which is currently being replaced with the more gentle pursuit of fly fishing.
Dr Jim Anderson
Dr Jim Anderson is a full time consultant in Radiology at Royal Perth Hospital and Head of Interventional Radiology. His
interests include oncological imaging and intervention with particular reference to the Prostate, Breast, Liver and Spine.
Dr Anderson was awarded Life Membership of the Royal Australian and New Zealand College of Radiologists at the Melbourne
2011 meeting and is Senior Lecturer for the University of Western Australia.
His major contributions and interests include:
Performing the first 50 Trans arterial Yttrium 90 treatments of colorectal liver cancer metastases (a procedure now
widely practised);
Research on Breast MRI resulting in a Medicare rebate for government funding for Breast MRI in women at higher
risk for the development of breast cancer;
Performing the first percutaneous Vertebroplasties in Australia for pain relief;
Trans-perineal Biopsy of the prostate;
CT perfusion of the prostate;
MRI of the Prostate.

Caves House Hotel
Yallingup Caves House Hotel is the quintessential Australian pub and has
been the resident watering hole for the locals since 1905. Tens of thousands
of patrons have frequented the pub for its famous summer Sunday sessions
over the decades.
In the early days, visitors were transported to the hotel by horse and buggy
from Busselton and the hotel has been a honeymoon destination for over
100 years. We even have a resident ghost named Molly, who wanders the
hotel to this day!
Yallingup translates to ‘place of love’ and indeed, Yallingup Caves House
Hotel is the ideal setting for wedding ceremonies, receptions and stunning
wedding photographs in our extensive heritage listed gardens and art deco
hotel.
The hotels' rooms are beautifully appointed and many overlook the heritage
listed gardens or beer garden. It's a great place to unwind and relax close to
the beach and yet still be a part of the vibrant pub activity below.
Surfers have stomped through the halls since the 1950's as Yallingup Beach - just a stone's throw away - is
the birthplace of surfing in WA.
Currently under new management with a revamped menu featuring classic Aussie pub grub combined with
bistro style dining, Yallingup Caves House Hotel plays tribute to its past and embraces casual service with a
smile. Welcoming families and locals, the old' jewel of the south west is set to shine again!
Questions
Meeting Queries:
Hotel Queries:
Contact Melvyn Kuan or Audrai O’Dwyer
Please see reception at the Caves House Hotel
Dress Code
The dress code for the meeting is casual; however, please not Saturday night dinner is Black-tie!
Meals
Morning tea and lunch will be served with industry representatives in the exhibition marquee.
Acknowledgements
The WA Section wishes to thank the convenor Melvyn Kuan for organising this meeting. We also wish to
extend our thanks to the guest speakers for their time.

Scientific Program
Friday 14th September, 2012
Drawing Room, Caves House Hotel
1300-1700 TA&E—Drawing Room
Sandwiches, tea and coffee provided
Saturday 15 th September, 2012
Yallingup Room, Caves House Hotel
0730 Registration Open & Industry Display with tea/coffee
0800-0805 Welcome from Convenor
0805-0810 Message from Sponsors Hospira
0810-0820 Erectile Rehab and Sexual Health David Millar
0820-0830 Penile Prosthesis Experience Shane LaBianca
0830-0850 Panel Discussion
0850-0905 Making an idea progress to commercial reality Prof Wilhelm Bauer
0905-0910 Message from Sponsors Abbott
0910-0925 MRI of the prostate: Perth Experience Jim Anderson
0925-0945 MRI Prostate Future Nathan Lawrentschuk* (Austin Hospital Vic)
*Sponsored by Abbott
0945-1000 MRI Prostate - The Birmingham Experience Prashant Patel
1000-1015 Panel Discussion
1015–1030 Morning Tea with Trade in Marquee
1030-1035 Message from Sponsors Ferring
1035-1050 Urology Health Care Provision to the North West Dickon Hayne
1050-1105 Training Urologists: The challenges Melvyn Kuan
1105-1120 Workforce Workshop - The future planning of Urology Services WA - Louis Landau
1120-1150 Panel Discussion
1150-1200 Cancer Collaborative Network: Testicular Cancer Centres Dickon Hayne
1200-1220 Panel Discussion
1220-1230 Radiology Quiz
1230-1330 Lunch in Trade Marquee
Free Afternoon
1830 Bus Leaves for Cullens’ Winery
1900-Late Black-tie Dinner at Cullens’ Winery

Scientific Program
Sunday 16th September, 2012
Yallingup Room, Caves House Hotel
0800-0900 AGM
0905-0910 Message from Sponsors CSL
0910-0925 Tea Break outside Yallingup Room
0925-0930 Message from Sponsors AstraZeneca
0930-0940 Use of Memokath at Shenton Park Hospital Jennifer Kong
0940-0950 Does LigasureTM seal small lymphatic vessels Isaac Thyer
0950-1000 Penile Cancer : The WA experience Kevin McMillan
1000-1010 Radiofrequency Ablation for Renal Tumours in Royal Perth Hospital Alarick Picardo
1010-1020 Retrograde ureteric stent insertion in the management of infected obstructed kidneys
Stephanie Flukes
1020-1030 Stage migration in Bladder Cancer Callum Logan
1030-1040 Management of duplex systems and ureteroceles in WA Bhanu Prakash
1040-1100 Morning Tea in Trade Marquee
1100-1105 Message from Sponsors BostonScientific
1100-1110 The Overactive Bladder: Botox and Sacral Neuromodulation Jeff
Thavaseelan
1110-1120 Use of drains in radical prostatectomy: A change in paradigm Jerrard Ghossein
1120-1130 10 year review of scrotal exploration for acute scrotum in children with a focus on
post-op chronic orchalgia Naeem Samnakay
1130-1140 Prashant Patel TBA
1150-1200 Nathan Lawrentschuk* TBA
Sponsored by Abbott
1200-1230 Tony Low Oration - Representative of WWF
1230-1300 Close of meeting and Lunch in Trade Marquee
End of Meeting

Social Program
Saturday September 15 th
Morning Activity:
Self-defence workshop and martial arts demonstration
Mr Sam Richards (a professional martial arts instructor) and some of his students will teach you some practical
techniques on self-defence for the novice. His techniques will include grappling and a sword skills demonstration.
The workshop will cater for all levels of experience, and will include a stretching and yoga class.
Spectators are also welcome.
TIME:
9am – 11am
LOCATION: Lawn area, Seashells
COST:
Included in registration fee
EQUIPMENT: Bring suitable active wear clothing.
Afternoon Activity:
Ngiligi Cave Explorer Adventure Tour
The Explorer Adventure Tour offers participants a chance to descend 45m below the earth’s surface with your expert
Cave Guide and explore the path of an Ancient Riverbed. On your return to the main Ngilgi Show Cave experience
your very own adventure by way of choosing which route through the cave you take to return to your
starting point. Each path you take presents a unique opportunity to enjoy a different adventure experience, just
like the challenge faced by the earliest Cave Explorers!
TIME:
Leave Seashells at 1345 to start tour by 1415 Duration of tour is generally 2+ hours
LOCATION: Ngilgi Cave, 76 Yallingup Caves Road Phone: +618 9755 2152
Own transport to caves will be required.
COST:
Approximately $68 per person. Ngilgi Caves will confirm the final cost depending on final
numbers.
EQUIPMENT: Light and helmet are supplied. Wear comfortable clothing such as tracksuit pants and a t-shirt
(it is not cold). Non marking enclosed footwear such as boots or runners is a must. Old clothes
are recommended as crawling is part of this tour.
AGE:
Suitable for children 10 years and up. Ratio of adults/supervisors in groups with children is a
minimum of 1:5
NUMBERS: Maximum group size is 12.
SAFETY CONSIDERATIONS: A reasonable degree of fitness is needed to visit Ngilgi Cave. Other conditions that may prohibit a
person from enjoying a safe visit to Ngilgi Cave include claustrophobia, fear of heights, fear of darkness, asthma and epilepsy.
A medical form must be submitted to the Cave Guide prior to the tour commencing, complete with details of all group
members’ medical conditions. It is important
to keep in mind that medical
help is not always readily available in
cave environments.
It is important to remember caves contain
rugged underground terrain and can be
hazardous places. They are dark, contain
loose rock and unstable slippery surfaces, low
roof areas and vertical drops. Ngilgi Cave is
45 m deep. This is equivalent to 14 floors of
a multistorey building, and as the route
through the cave is not direct the vertical
distance travelled is significantly more than
45m. The ancient riverbed section of the cave
does involve crawling, rock scrambling and squeezing through narrow gaps.

Social Program
Sunday September 16 th
Morning Activity:
Wardan Aboriginal Culture Centre
Stone Toolmaking Workshop - 10.00am
Using traditional materials gathered from the surrounding bushland, learn how to make a Wardandi knife.
Discover how to make bush glue from kangaroo dung and sap from trees, and take home your own
Wardandi knife.
More information on their website: http://www.wardan.com.au/
Please book this directly with Wardan via this link.
Single Tour - Adult $20, Child $10 (under 13 yrs) , Family $50 ( 2 Adults & 2 children)
Anytime Activities:
Yallingup Maze
Open 9am – 5pm
3059 Caves Rd, Yallingup
Phone 08 9756 6500
Directions From Dunsborough: head west on Caves Road towards Yallingup for 7.5km. Turn left to stay on
Caves Road and drive 7.5km south.
The Maze is built in timber and contains within the labyrinth 5 feature towers and bridges to explore.
There is one entry and one exit. In the event of wet weather there are indoor puzzles and games to
explore.

Abstracts
Management outcomes of Duplex System Ureterocele – Western Australian Experience
Dr Bhanu Prakash, Mr Naeem Samnakay, Mr Andrew Barker, Dr Japinder Khosa
PURPOSE – To review different treatment modalities, functional outcome and continence in children treated
for duplex system ureterocele.
MATERIALS AND METHODS – The medical records of patients with duplex system ureterocele treated between
2001 to 2011 were reviewed retrospectively
RESULTS – 22 cases of Ureterocele were identified. In 14 cases the ureterocele was diagnosed antenatally,
in 8 cases it was diagnosed after a urinary tract infection. Features of bladder outlet obstruction were present
in 3 cases. All patients had Renal ultrasound, Micturating cystourethrogram and Renal isotope scan as
initial workup. The ureterocele was associated with the upper moiety in 21 cases and lower moiety in 1
case. The upper moiety was functioning in 5 cases, of which 3 had associated ipsilateral lower moiety reflux.
The upper moiety was non-functioning in 16 cases, of which 9 had ipsilateral lower moiety reflux, 1
had ipsilateral upper moiety reflux, and 2 had contralateral reflux. Age at surgery ranged from 3 days to 96
months.
5 patients had puncture or incision of the ureterocele as initial procedure. 4 of these required upper pole
nephroureterectomy because of recurrent UTI.
5 patients with preserved upper moiety function underwent excision of ureterocele and common sheath
reimplant to stop reflux. None of these had further problems or UTI.
7 patients with non-functioning upper pole with no reflux to lower moiety underwent upper pole
nephroureterectomy. 3 of these had recurrent UTI and needed further surgery to correct VUR or decompress
persisting ureterocele.
5 patients with non-functioning upper moiety with reflux to lower moiety had upper pole nephroureterectomy
and simultaneous excision of ureterocele and lower moiety ureteric reimplantation. None of these
had further problems or UTI.
CONCLUSION –There is a significant need for secondary procedures after initial puncture/incision of
ureterocele or upper pole nephroureterectomy alone*7/12, 58.3%+. Patients who had initial complete excision
of ureterocele with either upper pole nephroureterectomy or conjoint reimplantation were cured and
did not need further intervention.

Abstracts
Radiofrequency Ablation for Renal Tumours in Royal Perth Hospital
Alarick Picardo
Introduction:
Widespread use of computerised tomography (CT) for abdominal symptoms has led to the earlier detection
of renal tumours, often before onset of symptoms and when these masses are a much smaller size. These
changes have been reflected in the surgical approach offered with nephron sparing techniques such as laparoscopic
partial nephrectomy being the preferred option in many centres. Additionally, in attempts to minimise
the morbidity of surgery, ablative therapies such as radiofrequency ablation and cryoablation have been
developed and used throughout the world.
Aim:
This presentation aims to review the use of radiofrequency ablation for renal tumours at Royal Perth Hospital
with regards to patient selection, complications, and oncologic outcome. A systematic literature review will
evaluate the role of RFA, current data, and the current issues/controversies expressed throughout the world.
Patients:
Inclusion criteria – all patients who have underwent radiofrequency ablation for a renal tumour at Royal
Perth Hospital.
Methods:
Retrospective analysis using patient records and imaging.
Structured systematic review of the literature
Does LigasureTM seal small lymphatic vessels? Results from an ex vivo, scavenged canine tissue model.
I. Thyer, A. Tan, A. Hamid
Introduction
Ligasure is a haemostatic surgical dissection that reliably seals blood vessels. Covidien claim Ligasure also
seals lymphatic vessels,1 which is relevant to urologists performing LND and particularly important in laparoscopy
with limited space. One penile cancer LND case series demonstrated reduced complications
(lymphoedema) with Ligasure.2 Several studies have shown Ligasure can seal large lymphatics3-5 and one
RCT has demonstrated a significantly reduced drain output in axillary node Ligasure dissection. 6 No study has
directly shown that Ligasure seals small lymphatics. This study aims to evaluate whether Ligasure can seal
small lymphatics using ex vivo canine spermatic cords.
Method
Dogs donated testes with spermatic cord attached. Each dog testis had the spermatic cord either Ligasured,
or Clipped (Gold Hem-o-lock) or no intervention (control). Patente blue dye was then injected into the testicular
parenchyma and the distal spermatic cord was observed after 5 minutes and 10 hours for macroscopic
presence of blue dye. Spermatic cords from one Ligasure and one Clip testis were sent for histological analysis
to examine for presence of dye proximal and distal to the intervention site.
Results and Conclusion To be advised.
References
http://www.Ligasure.com/Ligasure/pages.aspx?page=Products/Open/160291
Gallo, F. et al. The role of inguinal lymphadenectomy. Arch Esp Urol. 2002;55:5
Box, G. et al. Comparative study of in vivo. J Urol.2009;181:1
Novitsky, Y. et al. Evaluation of the efficacy of. Surg Innov.2005;12:2
Khelif, K. et al. Thoracoscopic Thoracic Duct Sealing. J Lap Ad Tech.2007;17:1
Cortadellas, T. et al. Electrothermal bipolar vessel. Int J Surg.2011;9:8

Abstracts
Is deterioration in bladder cancer survival attributable to stage migration? An analysis of WA Cancer
Registry Data for the periods 1982-2011
Logan C, Hawks C, Hayne D
We would like to present to the USANZ audience early results of a study into bladder cancer stage migration.
The aim of this project is to examine the WA Cancer Registry data on bladder cancer to determine
any degree of stage migration from the periods 1982-1986, 2000-2004 and 2004-2011. According to AIHW
data bladder cancer survival has decreased over time, rather than increased as has been the case for
almost all other cancer types.
Potential explanations for worsening survival in bladder cancer include:
Delayed diagnosis and subsequent stage migration
Underlying change in the disease pathophysiology (i.e. to a more aggressive type)
Worsening medical treatment of diagnosed disease
Different age distribution at diagnosis
Coding policy changes /erroneous data
We hypothesise that diagnostic delays, resulting in later diagnosis of bladder cancer at a more advanced
and less treatable stage represent a likely explanation of the worsening survival which has been shown. If
this is the case, stage migration will be demonstrable.
Clearly the AIHW 2008 and Cancer Australia 2007 data demonstrates a clear need for more research into
bladder cancer. Future research proposals need to be based on providing answers to current gaps in
knowledge. If it can be demonstrated that there has been a significant stage migration in bladder cancer,
this information would provide evidence for diagnostic delay and provide a useful basis for future research
and organisational efforts to improve outcomes for this common cancer.
References
Australian Institute of Health and Welfare & Australasian Association of Cancer Registries (2010). Cancer in
Australia: an overview, 2010. Cancer series no. 60. Cat. no. CAN 56. Canberra: AIHW.
Australian Institute of Health and Welfare, Cancer Australia & Australasian Association of Cancer Registries
(2008). Cancer survival and prevalence in Australia: cancers diagnosed from 1982-2004. Cancer Series no.
42. Cat.no. CAN 38. Canberra: AIHW.
Cancer Australia (2007). Cancer research in Australia: an overview of cancer research projects and research
programs in Australia 2003 to 2005. Retrieved 19th January 2012 from
http://www.canceraustralia.gov.au/sites/default/files/user-upload/publications/

Abstracts
OUTCOMES OF SCROTAL EXPLORATION FOR PAIN IN CHILDREN: A 12-YEAR STUDY
Matthew Jones, Andrew Barker, Japinder Khosa, Naeem Samnakay
Princess Margaret Hospital for Children, Perth
Aim
To investigate the range of causes of scrotal pain, the reasons and rate of surgical re-exploration, complication
rates of surgery and the entity of chronic orchialgia.
Background
Chronic orchialgia in children is a poorly studied disorder.
Methods
We performed a retrospective analysis of all scrotal explorations (n=1102) performed at princess Margaret Hospital
during the period of 2000-2011.
Results
The cause of pain at exploration was torted appendages in 71.1%, testicular torsion in 10.4%, suspected torsion/
detorsion in 6.7% and epididymoorchitis in 4.3%. The overall re-exploration rate at our institution was 47 out of
1102 (4.3%).
In 89 cases where there was a torted testicular appendage, only the symptomatic side was explored. 9.0% of
these re-presented with contralateral appendage torsion and therefore underwent re-exploration.
The post-operative complication rate overall was 5.9%. Post-operative complication rate after re-exploration was
10.6%.
A total of 19 patients of 1102 primary explorations (1.7%) were diagnosed with chronic orchialgia. This group of
patients had varied findings at their original surgery: 9 had appendage torsion, 3 had true torsion, 2 had epididymoorchitis,
1 had suspected torsion/detorsion and 3 had idiopathic scrotal oedema. 9 of the 19 with orchialgia
had a second exploration and were found to have suspected torsion/detorsion or no obvious cause for pain. In
most cases, reassurance and simple analgaesia was sufficient management, but some children required referral
to the chronic pain specialists.
Conclusions
Bilateral scrotal exploration for unilateral torted appendages is justified. Chronic orchialgia occurred in 1.7% of
children in this series.
References
1) Ben-Meir David, Deshpande Aniruddh, Hutson John M, et al. Re-exploration of the Acute Scrotum.. BJU Int.
Feb 2006;97:364-6
2) Cavusoglu, Yusuf Hakan & Karaman, Ayse & Karaman, Ibrahim & Erdogan, Derya & Aslan, Mustafa Kemal &
Varlikli, Onursal & Cakmak, Ozden. (2005). Acute scrotum -- etiology and management. Indian journal of pediatrics,
2005
3) Kamaledeen S, Surana R.Intermittent testicular pain: fix the testes. BJU International. 91(4):406-8, 2003 Mar.
4) S R Keoghane, ME Sullivan. Investigating and managing chronic scrotal pain. BMJ. 341:c6716, 2010.
5) Murphy FL, Fletcher L, Pease P.Early scrotal exploration in all cases is the investigation and intervention of
choice in the acute paediatric scrotum. Pediatric Surgery International. 22(5):413-6, 2006 May.
6) Joseph Nariculam, Suks Minhas, Ade Adeniyi, David J. Ralph, Alex Freeman. A review of the efficacy of surgical
treatment for and pathological changes in patients with chronic scrotal pain. BJU International. 99(5):1091-3,
2007 May.
7) Soccorso G, Ninan GK, Rajimwale A, Nour S.Acute scrotum: is scrotal exploration the best management?. European
Journal of Pediatric Surgery. 20(5):312-5, 2010 Sep.

Abstracts
Retrograde ureteric stent insertion in the management of infected obstructed kidneys
Flukes S, McMillan K, Rukin NJ
Department of Urological Surgery, Fremantle Hospital, Alma Street, Fremantle, WA
Introduction:
An infected, obstructed kidney is a urological emergency. Acute management is prompt decompression of
the collecting system. Classical teaching suggests that retrograde instrumentation of the infected system is
more hazardous than percutaneous nephrostomy, but clinical evidence does not support this view. We present
our experience with retrograde ureteric stent insertion as our primary treatment modality.
Methods:
We performed a prospective analysis of all infected obstructed cases presenting to Fremantle Hospital over a
seven-month period from February 2012 to August 2012. Inclusion criteria include clinical or microbiological
evidence of infection and radiological evidence of obstruction.
Results:
Twenty seven patients with an infected obstructed kidney, secondary to calculi, were included in the analysis.
Patients’ mean age was 57(19 - 88), with a male to female ratio of 13:14. The majority of patients were Caucasian
(85%). Positive microbiological cultures were found in 74%. Twenty-six percent of patients required
an ICU admission, of which 57% of these patients went to ICU pre-intervention. Ninety-six percent of patients
had a successful retrograde stent insertion, with only one patient requiring a nephrostomy secondary
to failed stent placement. Median length of stay was 5 days (1 – 21). The most common infective organism
was Escherichia coli (37%). There were no deaths in this series.
Conclusion:
Our series shows favorable results using a retrograde approach, with 96% successful stent placement. Early
pre- and post-operative urine and blood cultures are recommended to guide antibiotic therapy. In our experience,
retrograde stent insertion is a suitable first line treatment option.

Exhibitors - GOLD
CSL Biotherapies manufactures, markets and distributes
plasma-derived therapies, vaccines, immunohaemotology
products and anti venoms. We also in-license, market and
distribute a range of pharmaceutical products. Our heritage
underpins our strong commitment to research and development,
reliability, safety and quality. This philosophy
has resulted in the development of many life-saving products
and allowed us to play a key role in the collaborative
work that has delivered the world’s first vaccine against
cervical cancer.
Jennifer Whyte
Email: Jennifer.whyte@csl.com.au
AbbVie is a global, broad-based health care company devoted
to discovering new medicines, new technologies and new
ways to manage health. Our businesses span the continuum
of care, offering nutritional, pharmaceutical and diabetes care
products, as well as vascular devices and laboratory diagnostics.
We are committed to the area of urology and have been
involved in a number of initiatives to improve outcomes for
people living with prostate cancer.
Michael Katrantzis
Email: Michael.katrantzis@abbott.com
Ferring Pharmaceuticals is a Swiss-based research-oriented
pharmaceutical company that specialises in products in the
field of Urology/Oncology, Gastroenterology, Endocrinology
and Reproductive Health.
At this meeting, Ferring Pharmaceuticals is featuring FIRMA-
GON® (degarelix), a GnRH receptor antagonist. FIRMAGON® is
streamlined authority listed on the PBS for the treatment of
locally advanced (equivalent to Stage C) or metastatic
(equivalent to Stage D) carcinoma of the prostate.
Visit the Ferring stand to learn more about FIRMAGON® and
its reconstitution and administration process.
John Lehman
Email: John.lehman@ferring.com
Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing
Wellness by developing, manufacturing and marketing
products that help improve the productivity, safety and
efficacy of patient care. In February 2007, Hospira
acquired Mayne Pharma Limited to become the world
leader in specialty generic injectable pharmaceuticals.
With 70 years of service to the hospital industry, Hospira's
portfolio includes one of the industry's broadest
lines of generic acute-care and oncology injectables,
which help address the high cost of proprietary pharmaceuticals;
and integrated solutions for medication
management and infusion therapy. Headquartered
north of Chicago in Lake Forest, Ill., Hospira has approximately
15,000 employees worldwide. Hospira's
news releases and other information can be found at
www.hospira.com
Geneva Thurnbull
Email: Geneva.turnbull@hospira.com
Boston Scientific (NYSE: BSX) is a worldwide developer,
manufacturer and marketer of medical devices.
Every day, Boston Scientific works to develop medical
innovations in Endourology. We develop devices to
treat kidney stones, bladder stones, ureteral strictures,
urethral strictures, benign prostatic hyperplasia (BPH),
prostate and bladder biopsy, urinary retention, as well
as female urinary incontinence, and pelvic floor reconstruction
Jessica Cifelli
Email: jessica.cifelli@bsci.com
AstraZeneca excels in providing healthcare solutions
across eight areas of healthcare: cardiovascular, diabetes,
respiratory disease, gastrointestinal illness, rheumatology,
neuroscience, anaesthesia and pain management
and oncology.
AstraZeneca invests billions of dollars in research and
manufacturing, spending over $16 million globally every
working day on the research and development of
medicines that meet patient needs.
Jarrad Pozzi
Email: jarrad.pozzi@astrazeneca.com

Exhibitors
Cook Medical consists of nine business
units—Aortic Intervention, Critical Care,
Endoscopy, Interventional Radiology, Lead
Management, Peripheral Intervention,
Surgery, Urology and Women’s Health.
Individually, the units provide highly focused
expertise that aligns with your clinical
needs. Together, they form a comprehensive
source for clinical solutions. Cook
has been a leading supplier of medical
devices for urologists for over 30 years—
offering interventional and biodesigned
technologies that support diagnostic and
therapeutic procedures in adult and pediatric
urology; with an emphasis in stone
management and male and female pelvic
health.
Kell Jones
Email: kell.jones@cookmedical.com
Karla Arias
Email: Karla.arias@cookmedical.com
Beckman Coulter develops, manufactures
and markets products for complex biomedical
testing. Beckman Coulter’s Prostate
Health Index (phi), is a simple, noninvasive
blood test that is 2.5 times more
specific in detecting prostate cancer than
PSA and is proven to reduce the number of
prostate biopsies. It has also recently
gained FDA Approval.
Moira Rooney
Email: mrooney@beckman.com
Olympus is an innovative technology and service
provider, excelling in the field of Urology.
With the complete product portfolio in Urology
offering unique video scopes and bipolar
PlasmaButton Vaporisation in addition to our
range of Endourology consumable products,
we are the company to partner with for your
daily diagnostic and therapeutic requirements.
Kim Stephens
Email: kim.stephens@olympus.com.au
Kent Brinklow
Email: kent.brinklow@olympus.com.au
Ulco Medical is an Australian owned company
that has worked in close partnership with the
medical industry for over 40 years. We are
renowned for supplying innovative and reliable
medical products of superior quality that
not only meet, but exceed the demands of our
discerning client base.
While the technology we bring to the market
is a cornerstone to our achievements to date,
our real success has been delivered through
the quality of our people and partners. The
trust our partners, customers and employees
alike have in Ulco Medical is paramount to our
success. As a result, we encourage a culture of
corporate and social responsibility that underpins
our reputation in the market.
Kevin Scrimshaw
Email: kevin@ulcomedical.com
Since its beginnings in 1945, KARL
STORZ has established itself worldwide
as a company in the production
and sale of medical instruments. The
exciting addition of KARL STORZ Endoscopy
Australia Pty Ltd means that
the Australian healthcare market will
experience service, education and
support in line with the level of excellence
provided by the global KARL
STORZ Corporation.
Chantal Powell
Email: cpowell@karlstorz.com.au
Daniel Miocevich
Email: dmiocevich@karlstorz.com.au
Allergan is a global, technology-driven,
multi-specialty health care company pursuing
therapeutic advances to help patients
live life to their fullest potential..
Founded in 1950 and headquartered in
Irvine, California, Allergan Inc is a pharmaceutical,
biologics and medical devices
company.
Allergan Australia Pty Ltd was first established
in Sydney in 1968. Our product
offerings focus on the areas of Neurosciences,
Eye Care, Medical Aesthetics, and
Health (Obesity).
Katie Jennings
Email: Jennings_katie@allergan.com
MD Solutions Australasia are an Australian
owned and operated company specialising in
niche technologies in the world of medicine
and surgery. Drop by to see the latest advances
in the world of urological surgery, its treatment
and preventative measures for better
patient outcomes.
Xavier Lawrence
Email: Xavier.lawrence@mdsolutions.net.au
Marliyn Cheng
Email: Marilyn.cheng@mdsolutions.net.au

EXHIBITORS
AMS is the world's leading company focused on
developing, manufacturing and marketing medical
devices that restore male and female pelvic health.
AMS Australia utilises this global strength to provide
quality solutions and unmatched resources to
Urologists throughout Australia and New Zealand
covering prosthetic urology, BPH solutions and
female urology.
Our training initiatives, in surgery support, staff
knowledge and staff dedication sees us providing a
true partnership in numerous practices throughout
Australia and New Zealand for the long term.
Sanofi, a global and diversified healthcare
leader, discovers, develops and distributes
therapeutic solutions focused on patients’
needs. Sanofi has core strengths in
healthcare, with 7 growth platforms: diabetes
solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets,
animal health and the new Genzyme. Through
the acquisition of Genzyme, Sanofi has
strongly reinforced its footprint in rare diseases.
Larraine D’Souza
Email: Larraine.d’souza@sanofi.com
Medivenn has raised the bar on the
supply of medical equipment across
Asia. We supply only the highest quality
products and ensure our staff are fully
trained in the latest developments and
techniques to support you at all times.
Amish Kanji
Email:
akanji@endotherapeutics.com.au
Caroline McLaunchlan
Email: caroline@medivenn.com
Andria Betti
Email: andria@medivenn.com
Keith Boardman
Email: keith.boardman@ammd.com
Trudi Franklin
Email: Trudi.franklin@ammd.com
GlaxoSmithKline is a global research-based pharmaceutical
and healthcare company with a mission to
improve the quality of human life by enabling people
to do more, feel better and live longer.
In Australia, we provide about 1600 skilled jobs
across the country, working with researchers and
doctors to discover new ways of treating and preventing
disease.
We invest $58 million a year in local research and
development, and supply $477m million to Australia’s
pharmaceutical and medicinal exports.
Stanley D’Souza
Email: Stanley.x.d’souza@gask.com
Many respected brands.
One committed company.
At Covidien, we're passionate about making
doctors, nurses, pharmacists and other medical
professionals as effective as they can be.
From Autosuture to Valleylab, from Kendall to
Mallinckrodt, our industry-leading brands are
known worldwide for uncompromising quality
and reliability.
Covidien offers an extensive product line that
spans medical devices, imaging solutions,
pharmaceuticals and medical supplies, we
serve healthcare needs in hospitals, long-term
care and alternate care facilities, doctors’
offices and in the home.
We offer products in a number of speciality
healthcare areas, including Laparoscopic surgery,
Electrosurgery, Biosurgery, sleep therapy
and pain management.
Jason Soper
Email: jason.soper@covidien.com
Rhys Hosgood
Email: rhys.hosgood@covidien.com
Hayley Shuttleworth
Email: hayley.shuttleworth@covidien.com
At Medtronic, we're committed to Innovating
for life by pushing the boundaries
of medical technology and changing
the way the world treats chronic disease.
To do that, we're thinking beyond
products and beyond the status quo - to
continually find more ways to help people
live better, longer. With over
100,000 patients treated worldwide,
sacral neuromodulation offers longterm
stability for your bladder and bowel
control patients. To learn more,
please visit www.medtronic.com.au or
call 1800 668 670
Timothy Holwell
Email: Timothy.holwell@medtronic.com
Alison De Mattia
Email: Alison.de.mattia@medtronic.com